"Nuclear" Power of Science and Technology Innovation Center | Zhidao Biology: Focus on protein Research, from "Original Technology" to "Global Leading"

half past eight
With the continuous development of biotechnology
Protein as a medicine
It plays an increasingly important role in the treatment of human diseases.
At present, it has become one of the hot spots in international pharmaceutical research.
Located in Haidian District
Beijing zhidao biology science and technology co., ltd
It is an innovative platform enterprise in protein.
The company focuses on cancer immunotherapy and rare disease treatment.
At present, its protein renaturation technology.
It is in a leading position in the field of biopharmaceuticals in China.
Be in the first echelon of international related fields.

Leading protein preparation technology in China
"The whole logic of our protein directed renaturation technology is to use lower microorganisms, such as bacteria like Escherichia coli, to synthesize protein of higher organisms like humans, to produce a solid state of dead proteins in Escherichia coli, and to refold these proteins in vitro and restore their activity. Just like a boiled egg, with our technology, it can be restored to the state of egg white, and then chickens can be hatched. " Zhang Wei, executive director of Beijing Zhidao Biotechnology Co., Ltd. said.
"Generally speaking, the tertiary structure is a protein structure with complete biological function. In terms of renaturation process, some proteins are in a state of no biological activity after recombinant expression. Similar to kneading into a ball of wool, there is no structure that can produce biological functions. We denature it and pull it into a line, and then under the specific renaturation conditions we have screened, it folds again to form what we want, such as becoming a’ Chinese knot’ or a’ sweater’. " Liu Huijie, the company’s project assistant, further explained.

Whether biopharmaceuticals or biologics, the status of protein products is becoming more and more important, and how to get high-quality protein has always been the technical difficulty of related industries. Protein directed renaturation technology, one of the core technologies of Zhidao Biology, greatly reduces the manufacturing cost of recombinant protein, and has short research and development cycle and strong controllability. At the same time, it is difficult to imitate because of high technical barriers. With the unremitting efforts of the team, Zhidao Bio has also developed a number of cytokines and enzyme drugs with great technological difficulties and great competitiveness.
Breaking technological monopoly with innovation
In the interview, Liu Huijie told the reporter that Zhidao Bio is now producing a high-value enzyme called totipotent nuclease. It is understood that during the epidemic, the enzyme was restricted by a foreign "stuck neck" product, and there was a market gap in China for a time.
According to the demand, Zhidao Bio has optimized the production process in a short time, filling the blank of domestic products. At the same time, the production cost has been reduced by dozens of times, which has played a role in optimizing and reducing the cost of the entire industrial chain.

The reporter learned that a number of recombinant protein drug pipelines with independent intellectual property rights developed by Zhidao Bio-innovation directly point to the drugs for severe tumors and rare diseases that are urgently needed in the market and clinic and supported by the government, providing more ways for the treatment of severe and rare diseases.
Bring new hope to cancer patients
"There are several ways to treat cancer in general, one is surgery, the other is radiotherapy and chemotherapy, and the other is small molecule targeted drugs. However, because cancer cells expand very fast, small molecule targeted drugs are easy to develop drug resistance and need to be replaced frequently. In the end, they will face a dilemma of no drugs available." Liu Huijie said: "What we are mainly doing now is the direction of immunotherapy. One of our protein products is a cytokine product used in immunotherapy, which is equivalent to mobilizing the body’s own immunity and making it better identify tumors. It is a relatively mild and sustained treatment." Compared with traditional cancer treatment methods, protein products developed by Zhidao based on independent intellectual property technology have obvious advantages, and can overcome intractable diseases with a more efficient and safer immunotherapy method.

At the same time, Zhidao Bio has also made efforts to conquer major infectious diseases, and the company has made an attempt in the field of novel coronavirus by using "protein directional renaturation technology". "The COVID-19 vaccine we developed based on technology has completed the animal experiment. In the experimental stage, it was compared with the dimer and trimer recombinant COVID-19 vaccine on the market. Some indicators are better than the recombinant protein vaccine currently on the market." Xia Wenjuan, vice president of Zhidao Biology, introduced.

Whether in the field of rare diseases with a very small patient base or in the field of major infectious diseases involving social public health and safety issues, Zhidao Biology has corresponding research results. At present, its core products have basically taken shape, including cytokines and recombinant bovine trypsin.
Based on the company’s core technology, Zhidao Bio focuses on solving the core manufacturing and patent barriers in biopharmaceuticals and protein product development, aiming at breaking the monopoly of foreign countries on protein’s pharmaceutical engineering and manufacturing market and filling the gaps in domestic core technologies in related fields.
Zhang Wei said: "protein drugs are the development trend of biopharmaceuticals and even the whole pharmaceutical industry in the future.This requires innovative technology and future production capacity to be in our own hands.The gap between us and foreign countries in the biomedical industry lies in how to avoid the patent barriers of core biopharmaceuticals, protein drugs and protein products, and whether the production costs of high-quality raw materials and biopharmaceuticals are competitive. The vision of Zhidao Bio is to focus on these two core points, and gradually solve the patent barriers and manufacturing barriers. At the same time, based on Haidian, it will form a linkage with the upstream and downstream enterprises in Haidian, and quickly upgrade the technological iteration and upgrading of the biomedical industry in China. "

Aim for the road and stop at the best. Facing the new situation, Zhidao Bio has put forward new goals for its future development. While continuing to maintain the leading level in the field of cytokines, it will expand the advantages of drug development in protein to the fields of peptides, enzymes and so on. Using advanced protein technology to narrow the gap between China and the world’s leading edge in the field of life sciences, and become the global leader in scientific research in protein.
Come on, Haidian enterprises!
"Science and Technology Center" nuclear "power" is quite you!
"Nuclear" Power of Science and Technology Innovation Center "
Guiding unit: Haidian District People’s Government of Beijing.
Producer: Media Center in Haidian District, Beijing
This video "Zhi Dao Biology: protein’s scientific research leader facing the world"
Producer: Tong Zhiwei, Li Wei
Chief planner: Zhang Qingjie
Chief producer: Zhang Dongxu
Producer: Liu Wenting Yang Kaibo
Coordinator: Han Juanjuan Yang Kaibo
Director: Xie Chunyang
Camera: Root
Voice: Gong Kehan
Tweets in this issue
Text: Xie Chunyang Editor: Chen Naihe
Reporting/feedback